Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations: An update

Clinical Biochemistry

Volumn 31, Issue 5, 1998, Pages 345-351

  Trepanier, Daniel J ^a   Gallant, Heather ^b   Legatt, Donald F ^b   Yatscoff, Randall W ^a,b  

^a Isotechnika Inc   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450; DRUG METABOLITE; DRUG VEHICLE; FK 506 BINDING PROTEIN; N,N DIMETHYLACETAMIDE; RAPAMYCIN; TACROLIMUS;

AREA UNDER THE CURVE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; GRAFT SURVIVAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ERYTHROCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; TISSUE DISTRIBUTION; TRANSPLANTATION IMMUNOLOGY;

EID: 0032128447     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(98)00048-4     Document Type: Conference Paper

References (49)

1. Sehgal S.N., Baker H., Vezina C. Rapamycin (AY-22,989), A new antifungal antibiotic II. Fermentation, isolation and characterization. J Antibiot. 28:1975;727-732.
2. Morris R.E. Rapamycin antifungal, antitumour, antiproliferative and immunosuppressive macrolide . Transplant Rev. 6:1992;39.
3. Kimball P.M., Kerman R.H., Kahan B.D. Production of synergistic, but non-identical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation. 51:1991;486-490.
4. Metcalfe S.M., Richards F.M. Cyclosporine, FK506 and rapamycin some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells . Transplantation. 49:1990;798-802.
5. Dumont F.J., Staruch M.J., Koprak S.L., Melino M.R., Siga N.H. Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK506 and Rapamycin. J Immunol. 144:1990;251-258.
6. Kahan B.D., Chang J., Sehgal S.N. Preclinical evaluation of a new immunosuppressive agent, rapamycin. Transplantation. 52:1991;185-191.
7. Stepkowkski S.M., Chen H., Daloze P., Kahan D.B. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney and small bowel transplantation in the rat. Transplantation. 51:1991;22-26.
8. Collier D., Calne R., Thiru S., et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc. 22:1990;1674-1675.
9. Morris R.E., Wu J., Shorthouse R. A study of the contrasting effects of cyclosporine, FK506 and rapamycin on the suppression of allograft rejection. Transplant Proc. 22:1990;1638-1641.
10. Fryer J., Yatscoff R.W., Pascoe E.A., Thliveris J. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation. 55:1993;340-345.
11. Almond P.S., Moss A., Nakhleh R.F., et al. Rapamycin, immunosuppressive and tolerogenic effects in a porcine renal allograft model. Transplantation. 56:1993;275-281.
12. Yakimets W.J., Lakey J.R., Yatscoff R.W., et al. Combination low dose rapamycin and cyclosporine prolong canine pancreatic islet allograft survival rapamycin efficacy is blood-level related . Transplantation. 56:1993;1293-1298.
13. Kahan B.D., Gibbons S., Tejpal N., Stepkowski S.M., Chou T.C. Synergistic interaction of cyclosporine and rapamycin to inhibit immune performances for normal peripheral blood lymphocytes in vitro. Transplantation. 51:1991;232-239.
14. Tu Y., Stepkowski S.M., Chou T.C., Kahan B.D. The synergistic effects of cyclosporine, sirolimus and brequinar on heart allograft survival in mice. Transplantation. 59:1995;177-183.
15. Knight R., Ferraresso M., Serino F., Katz S., Lewis R., Kahan B.D. Low-dose rapamycin potentiates the effect of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation. 55:1993;947-949.
16. Peck C.C., Barr W.H., Benet L.Z., et al. Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. J Clin Pharm Ther. 51:1992;465-473.
17. Yatscoff R.W., Wang P., Chan K., Hicks D., Zimmerman J. Rapamycin distribution, pharmacokinetics, and therapeutic range investigations . Ther Drug Monit. 17:1995;666-671.
18. Zimmerman J.J., Kahan B.D. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol. 37:1997;405-415.
19. Brattström C., Tydén G., Säwe J., Herlenius G., Claesson K., Groth C.G. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc. 28:1996;985-986.
20. Johnson E.M., Zimmerman J.J., Duderstadt K., et al. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc. 28:1996;987.
21. Ferron G.M., Mishina E.V., Zimmerman J.J., Juslo W.P. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther. 61:1997;416-428.
22. Yatscoff R.W., LeGatt D., Keenan R., Chackowsky P. Blood distribution of rapamycin. Transplantation. 56:1993;1202-1206.
23. Honcharik N., Fryer J., Yatscoff R. The pharmacokinetics of rapamycin single-dose studies in the rabbit . Ther Drug Monit. 14:1992;475-478.
24. Yatscoff R.W., Faraci C., Bolingbroke P. Measurement of rapamycin in whole blood using reverse-phase high performance liquid chromatography. Ther Drug Monit. 14:1992;138-141.
25. Napoli K.L., Kahan B.D. Sample clean-up and high performance liquid chromatography techniques for measurement of whole blood rapamycin concentrations. J Chromatogr B. 654:1994;111-120.
26. Svensson J.O., Brattström C., Säwe J. Determination of rapamycin in whole blood by HPLC. Ther Drug Monit. 19:1997;112-116.
27. Chan K, Wang P, Scantina J, et al. Characterization of biliary rapamycin metabolites by ionspray liquid chromatography/mass spectrometry [abstract]. Proceedings of the 41st ASMS Conference on Mass Spectrometry and Allied Topics, San Francisco, May 31-June 4, 1993; 545.
28. Streit F., Christians U., Schiebel H.M., et al. Sensitive and specific quantitation of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 42:1996;1417-1425.
29. Jusko W.J., Ferron G.M., Mis S.M., et al. Pharmacokinetics of prenisolone during administration of sirolimus in patients with renal transplants. J Clin Pharmacol. 36:1996;1100-1106.
30. Satter M., Guengerich F.P., Yun C.H., Christians U., Sewing K.F. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 20:1992;753-761.
31. Goodyear N., Napoli K.L., Murthy J.N., Kahan B.D., Yatscoff R.W. Radioreceptor assay for sirolimus. Clin Biochem. 29:1996;457-460.
32. Gallant H.L., Yatscoff R.W. p70 S6 kinase assay a pharmacodynamic strategy for rapamycin, assay development . Transplant Proc. 28:1996;3058-3061.
33. Christians U., Sattler M., Schiebel H.M., et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 20:1992;186-191.
34. Wang P.C., Lim H.K., Chan K.W., et al. Isolation of ten metabolites from the bile of rats receiving rapamycin (sirolimus) intravenously. ISSX Proc. 8:1995;136.
35. Streit F., Christians U., Schiebel H.M., Meyer A., Sewing K.F. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-ms/ms after incubation with human liver microsomes. Drug Metab Dispos. 24:1996;1272-1278.
36. Gonschior A.K., Christians Uwe, Winkler M., Linck A., Baumann J., Sewing F.K. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem. 42:1996;1426-1432.
37. Wang C.P., Chan K.W., Schiksinis R.A., Scantina J.A., Sisenwine S.F. High performance liquid chromatographic isolation, spectroscopic characterization, and immunosuppressive activities of two rapamycin degradation products. J Liq Chromatogr. 17:1994;3383-3392.
38. Wang C.P., Lim H.K., Chan K.W., Schiksinis R.A., Scantina J.A., Sisenwine S.F. High performance liquid chromatographic isolation and spectroscopic characterization, of three major metabolites from the plasma of rats receiving rapamycin (sirolimus) orally. J Liq Chromatogr. 18:1995;2559-2568.
39. Baker H., Sidorowitz A., Sehgal S.N., Vezina C. Rapamycin (AY-22 989), A new antifungal antibiotic III. In vitro and in vivo. J Antibiot (Tokyo). 31:1978;537-545.
40. Stepkowski S.M., Napoli K.L., Wang M.E., Qu X., Chou T.C., Kahan B.D. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation. 62:1996;986-994.
41. Granger D.K., Cromwell J.W., Chen S.C., et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation. 27:1995;183-186.
42. Thliveris J.A., Yatscoff R.W., Mihatsch M.J. Chronic cyclosporine-induced nephrotoxicity- a rabbit model. Transplantation. 57:1994;774-776.
43. Thliveris J.A., Yatscoff R.W. Effect of rapamycin on morphological and functional parameters in the kidney of the rabbit. Transplantation. 59:1995;427-429.
44. Luo H., Chen H., Daloze P., Chang J.Y., St-Louis G., Wu J. Inhibition of in vitro immunoglobulin production by rapamycin. Transplantation. 53:1992;1071-1076.
45. Yatscoff R.W., Wang S., Chackowsky P., Lowes N., Koshal A. Efficacy of rapamycin, RS-61443 and cyclophosphomide in the prolongation of survival of discordant pig-to-rabbit cardiac xenografts. Can J Cardiol. 10:1994;711-716.
46. Murgia M.G., Jordan S., Kahan B.D. The side effect profile of sirolimus a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients . Kidney International. 49:1996;209-216.
47. Kahan B.D. Sirolimus a new agent for clinical renal transplantation . Transplant Proc. 29:1997;48-50.
48. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative. Pharmacolocical properties in vitro and in vivo. Transplantation. 64:1997;34-42.
49. Schuurman H.-J., Cottens S., Fuchs, et al. SDZ RAD, a new rapamycin derivative. Synergism with cyclosporine. Transplantation. 64:1997;32-35.